Abstract 62P
Background
Cervical intraepithelial neoplasia (CIN) is regarded as a precancerous condition of the cervix. The tumor microenvironment contains a large number of immune cells, in particular, tumor-associated neutrophils (Nph), as well as pro-inflammatory cytokines, including IL6, which causes chronic inflammation and immunosuppression. The role of IL6 in the onset and progression of CIN has been shown (Chen J, Wang L, 2022). Regulation of cytokine expression occurs at the transcriptional level, in the promoter region of the gene. For IL6, a single nucleotide polymorphism (SNP) with a substitution at position -174G→C has been described that is associated with the risk of breast cancer. IL6 polymorphism (rs2069837) is significantly associated with an increased risk of cervical cancer (Das AP, et al, 2022). However, there is no data on the involvement of SNP IL6 C-174G (rs1800795) in the occurrence and development of CIN. The aim of the study was to evaluate the role of IL6 (C-174G) polymorphism in the development of CIN.
Methods
The study included 60 patients diagnosed with high-grade squamous intraepithelial lesions (CIN II, CIN III and cancer in situ) and 30 somatically healthy women (control). The study was conducted in accordance with the requirements of the ethics commission of UlSU. The level of IL6 was determined in Nph lysate by ELISA method (Vector-Best, Russia). The presence of SNP IL6 C-174G was assessed by polymerase chain reaction with restriction enzyme analysis using RsaI endonuclease (SibEnzyme, Russia). Electrophoresis was carried out in 1.5% agarose gel. Statistical processing was carried out using Statistica 13.
Results
It was found that the -174G* allele is more common in the group with lesions of the cervix (75.7%) than in the control (53.3%). The risk of developing CIN increased with an increase in the level of IL6 in Nph with CIN (9.69 (6.89-10.85) vs 1.33 (0.78-2.25), p=0.015) and the presence of the -174G allele * (OR=0.411, 95% CI 0.220-0.768, p=0.005) (χ2=23.4, p=0.001).Simultaneous assessment of the level of IL6 in Nph and SNP IL6 C-174G allows predicting the development of CIN with sensitivity (0.769) and specificity (0.897).
Conclusions
The presence of IL6 polymorphism (C-174G) and an elevated level of IL6 in Nph indicate the possibility of CIN.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract